Welcome to the e-CCO Library!

search
                             
search by: 
Filter:
P607

Histologic activity after acute treatment with multimatrix mesalazine for ulcerative colitis may predict long-term remission status

Authors:

G. D'Haens*1, G. De Hertogh2, J.R. Turner3, H. Wan4, B. Adeyi4, D.T. Rubin5

1Academic Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, 2University Hospitals Leuven, Department of Pathology, Leuven, Belgium, 3The University of Chicago Medicine, Department of Pathology, Chicago, IL, United States, 4Shire, Biostatistics, Wayne, PA, United States, 5The University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, United States

P608.

Mesalazine suppository use – ECCO guideline vs. real life

Authors:

R. Hofmann, L. MacKenzie, Tillotts Pharma, Medical Affairs, Rheinfelden, Switzerland

P608. Azathioprine versus mesalazine for prevention of post-operative clinical recurrence in Crohn's disease patients with endoscopic recurrence: follow-up data of a randomised, double-blind, double-dummy, 1-year, multicentre trial
Authors:

W. Reinisch1, S. Angelberger1, W. Petritsch2, O. Shonova3, M. Lukas4, R. Greinwald5, R. Mueller5, E.F. Stange6, K. Herrlinger7, 1Allgemeines Krankenhaus Wien, Klinische Abt. für Gastroenterologie und Hepatologie, Vienna, Austria, 2Medizinische Universitätsklinik Graz, Klinische Abt. für Gastroenterologie, Graz, Austria, 3Nemocnice Ceske Budejovice, Gastroenterologicke oddeleni, Ceske Budejovice, Czech Republic, 4Klinické centrum Iscare Lighthouse, Prague, Czech Republic, 5Dr Falk Pharma GmbH, Dept. of Clinical Research & Development, Freiburg, Germany, 6Robert Bosch Krankenhaus, Internal Medicine I, Stuttgart, Germany, 7Asklepios Klinik Nord – Standort Heidberg, Innere Medizin I, Hamburg, Germany

P608

Hypovitaminosis D correlates with a more severe disease course in Inflammatory Bowel Disease patients

Authors:

G. Tapete, V. Almerigogna, F. Bucciero, A. Cozzi, M. Giannotta*, G. Macrì, S. Milani, M. Milla

AOU Careggi, Regional Referral Center fo Inflammatory Bowel Disease - Gastroenterology 1 Division, Florence, Italy

P609. 5-Aminosalicylate (5-ASA) induced nephrotoxicity in inflammatory bowel disease
Authors:

K. So1, C. Bewshea2, G. Heap1, A. Muller3, M. Delaney4, T. Daneshmend1, C. Mulgrew5, R. D'Souza5, J. Kwan5, P. Irving6, T. Orchard7, A. Hart8, E. Tsianos9, V. Annese10, M. Silverberg11, G. Watermeyer12, D. Renata13, G. Radford-Smith14, R. Gearry15, R. Oram5, IIBDGC16, R. Russell17, D. Wilson18, M. Parkes19, J. Satsangi20, R. Weersma21, I. Lawrance22, A. Holden23, C. Lees20, T. Ahmad1, 1Royal Devon and Exeter Hospital, Gastroenterology, Exeter, United Kingdom, 2Royal Devon and Exeter Hospital, IBD Pharmacogenetics Research, Exeter, United Kingdom, 3Kent and Canterbury Hospital, Gastroenterology, Canterbury, United Kingdom, 4Kent and Canterbury Hospital, Renal Medicine, Canterbury, United Kingdom, 5Royal Devon and Exeter Hospital, Renal Medicine, Exeter, United Kingdom, 6Guy's and St Thomas' Hospital, Gastroenterology, London, United Kingdom, 7St Mary's Hospital, Gastroenterology, London, United Kingdom, 8St Mark's Hospital, Gastroenterology, London, United Kingdom, 9University of Ioannina, Gastroenterology, Ioannina, Greece, 10Azienda Ospedaliero Universitaria (AOU), Gastroenterology, Careggi, Italy, 11Mount Sinai Hospital, Gastroenterology, Toronto, Canada, 12Groote Schuur Hospital, Gastroenterology, Cape Town, South Africa, 13University Hospital Padua, Gastroenterology, Padua, Italy, 14Royal Brisbane and Women's Hospital, Gastroenterology, Brisbane, Australia, 15University of Otago, Gastroenterology, Christchurch, United Kingdom, 16Wellcome Trust Sanger Institute, United Kingdom, 17Yorkhill Hospital, Gastroenterology, Glasgow, United Kingdom, 18University of Edinburgh, Paediatric Gastroenterology, Edinburgh, United Kingdom, 19Addenbrooke's Hospital, Gastroenterology, Cambridge, United Kingdom, 20Western General Hospital, Gastroenterology, Edinburgh, United Kingdom, 21University Medical Center, Gastroenterology, Groningen, Netherlands, 22Fremantle Hospital, Gastroenterology, Fremantle, Australia, 23International Serious Adverse Event Consortium, Chicago, United States

P609.

Long-term prognosis of Crohn's disease and its temporal change between 1981–2012: a hospital-based cohort study from Korea

Authors:

S.-K. Yang, S.H. Park, S.-J. Myung, J.-S. Byeon, K.-J. Kim, B.D. Ye, D.-H. Yang, K.W. Jung, J.-H. Kim, S.-K. Park, H.-S. Lee, H.J. Lee, J.-B. Kim, University of Ulsan College of Medicine, Asan Medical Center, Gastroenterology, Seoul, South Korea

P609

Efficacy of cytapheresis for remission induction therapy and dermatological manifestations of active ulcerative colitis

Authors:

O. Nomura*, T. Osada, T. Shibuya, D. Ishikawa, K. Haga, N. Sakamoto, T. Ogihara, S. Watanabe

Juntendo University, Gastroenterology, Tokyo, Japan

P610. “Living Well with IBD”: The role for structured education and non-medical intervention in enhancing quality of life
Authors:

O. Kelly1, M. Forry1, E. McDonnell1, J. Wilson-O'Raghallaigh1, S. Patchett1, 1Beaumont Hospital/Royal College of Surgeons in Ireland, Gastroenterology, Dublin, Ireland

P610.

Life experiences of patients with perianal Crohn's fistulae

Authors:

N.A. Yassin1, L. Dibley2, H.-L. Sim1, R.K.S. Phillips1, A.L. Hart1, C. Norton2, 1St Mark's Hospital, and Academic Institute, London, United Kingdom, 2King's College London, Florence Nightingale School of Nursing and Midwifery, London, United Kingdom

P610

OSTEOPATHY AND IMPROVING THE QUALITY OF LIFE IN CROHN'S DISEASE

Authors:

M. Orofino*1, J.-C. Grimaud2

1Collège Ostéopathique de Provence Aix-Marseille, Research department, Marseille, France, 2Hôpital Nord, Gastroenterology Unit, Marseille, France

P611. “An old and inexpensive drug to minimize the side effects of a new and expensive one”: Colchicine for the skin lesions induced by the tumor necrosis factor-alpha inhibitors, a case-series study
Authors:

J.M. Mella1, R. Gonzalez1, B. Vizcaino1, G. Casas1, M. Larralde1, S.C. Pedreira1, L. Boerr1, 1Hospital Aleman, Buenos Aires, Argentina

P611.

Is there an association between inflammatory bowel disease and Parkinson's disease?

Authors:

M. Johnson1, K. Lithgo1, T. Price2, 1Luton & Dunstable University Hospital foundation trust NHS, Gastroenterology, Luton, United Kingdom, 2The Luton & Dunstable University Hospital Foundation Trust NHS, Gastroenterology, Luton, United Kingdom

P611

First intestinal resection in Crohn's Disease . A long term prospective study

Authors:

N. Bounab*1, A. Balamane1, L. Kecili1, A. Bousseloub2, K. Belhocine1, K. Layaida1, N. Kaddache1, L. Gamar1, T. Boucekkine1, S. Berkane1

1CHU Mustapha, Faculty of Medicine, Algiers, Algeria, 2Hôpital Central de l'armée , Faculty of Medicine, Algiers, Algeria